Catalyst Brief

← Calendar

Readoutin 14d

Clarity Pharmaceuticals Ltd — 64Cu-SAR-bisPSMA

Phase 3 primary completion: 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer.

Date
Dec 2026
Type
Readout
Indication
Prostate Cancer

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.